Which Biotech Stocks to Invest In? Best Biotech Stocks in 2019

Biotech stocks may not be the most favorable stock investments when it comes to the level of risk, as well as levels of volatility that may hinder the value of biotech stocks in the market.

This is usually the case because biotech companies may suffer the consequences of failing to match regulatory requirements in compliance with the Food and Drug Administration.

However, those biotech companies that are standing up as profitable all have strong earnings and fast growth that can result in profit returns through stocks.

Top 3 Biotech Stocks in 2019: Ligand Pharmaceuticals (LGND)

Even though Ligand Pharmaceuticals stock is following downtrends with some of the latest closing during the last days of May 2019, Ligand is said to be doing more than well.

In addition to reporting 78% growth in revenues for 2018, Ligand has a market cap of 2.24 billion dollars.

Unlike many other companies in the sector, Ligand is not producing treatments, but is working on creating platforms for drug manufacturers.

Best Biotech Stocks: Corcept Therapeutics (CORT)

Corcept Therapeutics is most certainly one of the biotech companies with the fastest growth rates in the market. In the period from 2013 to 2018, Corcept managed to increase earnings per share by 186%.

Additionally, complete response rate rising to 90 and beyond, while RS rating is middling at the rate of 58.

Best Biotech Stocks: Vertex Pharmaceuticals (VRTX)

Vertex is most possibly one of the most interesting biotech stocks in the market in 2019 as the company is holding dominance in treating cystic fibrosis with therapeutics they have developed.

Revenue is up by 22% in the period of 12 months since 2018, in addition to doubling EPS counting from 2017.

The company has a market cap of 3.04 billion dollars with growth rate set at 129% in the 5-year period. Complete response rate is 87 with RS rate set at 43.

Disclaimer: The information on this site is provided for discussion purposes only, and should not be misconstrued as investment advice. Under no circumstances does this information represent a recommendation to buy or sell securities.